BriaCell Partners with Waisman Biomanufacturing to Manufacture and Supply Prostate Cancer Immunotherapy

BriaCell Therapeutics Corp. has entered a manufacturing service agreement with Waisman Biomanufacturing at the University of Wisconsin–Madison, to manufacture Bria-Pros™, BriaCell’s off-the-shelf personalized immunotherapy for prostate cancer, for anticipated use in clinical studies.